Satraplatin in the treatment of hormone-refractory prostate cancer

BJU International

Volumn 96, Issue 7, 2005, Pages 990-994

  Sternberg, Cora N ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; ONDANSETRON; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; SATRAPLATIN; TAXANE DERIVATIVE;

ANEMIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; HUMAN; LIVER TOXICITY; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PREDNISOLONE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 27444448140     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05799.x     Document Type: Review

References (22)

1. American Cancer Society. Cancer Facts & Figures 2005 Atlanta, Ga: 2005: 12
2. Eisenberger MA, De Wit R, Berry W et al. A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2004; 23: Abstract 4
3. Petrylak D, Tangen C, Hussain M et al. SWOG 99-16. Randomized phase III trial of docetaxel (D) /estramustine (E) versus mitoxantrone (M) /prednisone (, p.) in men with androgen-independent prostate cancer (AIPCA). Proc Am Soc Clin Oncol 2004; 23: Abstract 3
4. Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001; 19: 2509-16
5. Rosenberg JE, Small EJ. Second-line chemotherapy for hormone-refractory prostate cancer: has the time come? Clin Prostate Cancer 2004; 3: 122-4
6. Assikis VJ, Simons JW. Novel therapeutic strategies for androgen-independent prostate cancer: an update. Semin Oncol 2004; 31 (Suppl. 4): 26-32
7. Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug. Expert Opin Investig Drugs 2000; 9: 1373-82
8. Twentyman PR, Wright KA, Mistry P, Kelland LR, Murrer BA. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 1992; 52: 5674-80
9. Kelland LR, Abel G, McKeage MJ et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cydohexylamine platinum (IV): an orally active platinum drug. Cancer Res 1993; 53:2581-6
10. Mellish KJ, Kelland LR, Harrap KR. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 1993; 68: 240-50
11. Rose WC. Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models. Cancer Chemother Pharmacol 1997; 40: 51-6
12. Amorino GP, Mohr PJ, Hercules SK, Pyo H, Choy H. Combined effects of the orally active cisplatin analog, JM216, and radiation therapy in antitumor therapy. Cancer Chemother Pharmacol 2000; 46: 423-6
13. Wosikowski K, Rattel B, Caligiuri M et al. Cytotoxic activity of satraplatin (JM216) and its metabolites in human prostate carcinoma cell lines. Presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR) Orlando, Florida. Abstract 4614, March 29, 2004
14. McKeage MJ, Mistry P, Ward J et al. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995; 36: 451-8
15. McKeage MJ, Raynaud F, Ward J et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997; 15: 2691-700
16. McKeage MJ, Kelland LR, Boxall FE et al. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cydohexylamine-platinum (IV) (JM216) in vivo. Cancer Res 1994; 54: 4118-22
17. Beale P, Raynaud F, Hanwell J et al. Phase I study of oral JM216 given twice daily. Cancer Chemother Pharmacol 1998; 42: 142-8
18. Kurata T, Tamura T, Sasaki Y et al. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) administered once a day for five consecutive days: a phase I study. Jpn J Clin Oncol 2000; 30: 377-84
19. Sessa C, Minoia C, Ronchi A et al. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann Oncol 1998; 9: 1315-22
20. Peereboom D, Wood L, Connell C et al. Phase II trial of oral platinum (JM-216) in hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1998; 17: Abstract 1210
21. Sternberg CN, Whelan P, Hetherington J et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005; 68: 2-9
22. Sternberg CN, Hetherington J, Paluchowska B et al. Randomized phase III trial of a new oral platinum, satraplatin (JM-216) plus prednisone or prednisone alone in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2003; 22: Abstract 1586